MC Plus Material – 15_Overview of the FY2026 Medical Fee Revision 15. Appropriate Evaluation of Medical Technologies Page 50 – Center for Health Policy Information

News Highlights

News regarding a document from the Center for Health Policy Information (50 pages) focusing on the “Appropriate Evaluation of Medical Technologies” within the overview of the FY2026 medical fee revision. Key points for M&A and business succession include mid-to-long-term management and succession strategies considering the revision cycle, economies of scale through group formation (maintaining facility standards, distributing equipment investment burdens), and utilizing tax benefits by transitioning to specific or social medical corporations.

M&A Medical Editorial Department’s Perspective

The FY2026 medical fee revision prominently features a review of medical technology evaluations, which can directly impact the revenue structure of individual medical institutions. In particular, institutions with advanced medical technologies or specialized departments need to pay close attention to fluctuations in their evaluation levels. Incorporating these medical fee trends is essential for mid-to-long-term management strategies, and consequently, business succession strategies, that consider the revision cycle. For example, medical institutions reliant on technologies facing stricter evaluations may be able to maintain or enhance their competitiveness by leveraging the economies of scale from group formation to maintain facility standards and distribute equipment investment burdens. Furthermore, considering a change in corporate status (to a specific or social medical corporation) to optimize tax schemes can lead to improved cash flow during succession and reduced burden on successors. M&A and business succession, viewed not just as cost reduction but as a redesign of the revenue structure and accompanying organizational restructuring, are becoming increasingly important.

Points Highlighted by This News

• The “Appropriate Evaluation of Medical Technologies” in the FY2026 revision is highly likely to directly affect the profitability of individual medical institutions.
• Formulating mid-to-long-term management and succession strategies that consider the revision cycle will determine the sustainability of medical institutions.
• Maintaining facility standards and distributing equipment investment burdens through group formation contributes to the management stability of individual medical institutions.
• Transitioning to a specific or social medical corporation can be an option for business succession through optimization of tax schemes.

Practical Questions Arising from This News

• How might the evaluation of the medical technologies our institution focuses on change in this revision?
• If we form a group, how specifically can facility standards be maintained and equipment investment burdens be distributed?
• What are the merits and demerits of transitioning to a specific or social medical corporation, and is it applicable to our institution?

If You Feel “Should I Consult Too?”

Do you want to specifically understand the impact of the FY2026 medical fee revision trends, particularly the review of medical technology evaluations, on your institution’s management? If you are considering discussing options for mid-to-long-term management strategies in anticipation of the revision, or business succession options such as group formation or corporate status transition, with expert advice, it is worth considering consulting with an M&A intermediary company. This can be the first step towards developing an optimal strategy tailored to your institution’s current situation and future vision.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis as a certified M&A support institution by the Small and Medium Enterprise Agency. Consultations are handled with strict confidentiality. Free consultation here